Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced the appointment of Jeffrey R. Jasper, Ph.D., as Senior Vice President and Head of Research, and the promotion of Diana Chung to Senior Vice President and Chief Development Officer. Dr. Jasper brings over 28 years of industry experience, having held key roles at Rubedo Life Sciences and Merck. Chung has over 20 years of experience in drug discovery and clinical development. Terns aims to advance its pipeline towards a combination trial for NASH in 2022, leveraging the expertise of its strengthened leadership team.

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on serious diseases like non-alcoholic steatohepatitis (NASH), will showcase its progress at upcoming investor conferences. The key events are the 40th Annual J.P. Morgan Health Care Conference on January 13, 2022, at 11:15 a.m. ET, and the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10, 2022, at 7:00 a.m. ET. Interested parties can access live audio webcasts and replays on Terns' investor relations website.

Terns Pharmaceuticals reported strong progress in its clinical pipeline and financial health for Q3 2021, with cash reserves of $177 million projected to sustain operations into 2024. The company announced positive top-line data from TERN-501 supporting its role as a promising THR-β agonist in treating non-alcoholic steatohepatitis (NASH), and is set to initiate new trials in 1H 2022. The third quarter net loss was $11.8 million, slightly higher than the previous year, but R&D expenses rose to $7.2 million aimed at advancing its clinical candidates.

Terns Pharmaceuticals announced positive results from the Phase 2a LIFT Trial of TERN-101, demonstrating significant decreases in cT1, a marker of liver inflammation and fibrosis, over 12 weeks of treatment. The trial showed TERN-101 to be safe and well-tolerated, correlating cT1 improvements with reduced clinical event risks. Additionally, Phase 1 data for TERN-501 indicated well-tolerated single doses leading to significant LDL decreases and SHBG increases, pointing to its potential efficacy in treating NASH. Both compounds are pivotal in Terns' NASH treatment strategy.

Terns Pharmaceuticals reported positive Phase 1 clinical trial results for TERN-501, a THR-β agonist targeting non-alcoholic steatohepatitis (NASH). The trial showed that TERN-501 was generally safe, well-tolerated, and demonstrated favorable pharmacokinetic properties with a half-life of over 13 hours. Significant reductions in LDL cholesterol of up to 28% and marked increases in sex hormone binding globulin were observed. Terns plans to initiate an FXR/THR-β agonist combination trial in NASH in the first half of 2022.

On October 18, 2021, Terns Pharmaceuticals announced three accepted abstracts for presentation at The Liver Meeting® Digital Experience 2021, focusing on their non-alcoholic steatohepatitis (NASH) programs. Key presentations include:

• TERN-101: Favorable safety and efficacy from the Phase 2a LIFT Study.
• TERN-501: Well-tolerated in first-in-human trials, showing dose-dependent cholesterol changes.

These findings underscore Terns' commitment to developing effective therapies for chronic liver diseases.

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 5th Annual NASH Investor Conference set for October 12, 2021, at 2:30 p.m. ET. The company is focused on developing therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases, featuring a portfolio that includes three clinical-stage programs and a preclinical program. A live audio webcast of the presentation will be available on Terns’ investor relations page, with a replay archived for 30 days.

Terns Pharmaceuticals has appointed Dr. Ann E. Taylor to its Board of Directors. With over 35 years in drug development, including her tenure as Chief Medical Officer at AstraZeneca, Dr. Taylor is expected to bring valuable expertise to Terns, particularly in developing treatments for non-alcoholic steatohepatitis (NASH) and chronic liver diseases. Terns is known for its innovative therapeutic approaches, including a diverse pipeline featuring small-molecule therapies aimed at addressing NASH.

Terns Pharmaceuticals has completed patient enrollment for Part 1 of the AVIATION Trial, a Phase 1b study for TERN-201, a selective VAP-1 inhibitor targeting chronic liver inflammation and fibrosis in NASH patients. Preliminary top-line data is expected in 1Q 2022. The trial aims to assess the safety and tolerability of TERN-201 in comparison to a placebo over 12 weeks. TERN-201 has shown promise in preclinical studies, and the company received FDA Fast Track Designation for the treatment of NASH.